zlacker

>>giulio+(OP)
>The share of U.S. households reporting at least one user rose from about 11% in late 2023 to more than 16% by mid-2024.

I was wondering how you could get such a high impact overall. But it seems one in 6 households are on GLP-1 drugs in the US.

In my friend circle in Germany I don't even know one single person on this stuff.

It's insane to me that so many people need these to get off the processed foods killing them in the US.

>>carlmr+B5
I am not American, but I think you are unfairly dismissing the massive benefits GLP-1s have for people who struggle to maintain a healthy diet. It really feels like a miracle drug.

> It's insane to me that so many people need these to get off the processed foods killing them in the US.

Your comparison of your friends in Germany vs "insanity" in the US doesn't feel relevant

>>seedle+L6
I think you are misreading the comment you are replying to:

> Your comparison of your friends in Germany vs "insanity" in the US doesn't feel relevant

It's incredibly relevant, why are GLP-1s less needed in Germany vs. US (and other countries like Canada)? This is the insanity they are talking about, not the users of the medication.

>>Ensorc+u9
> It's incredibly relevant, why are GLP-1s less needed in Germany vs. US

Aside from whether the local healthcare coverage will pay for it, and the rate of GLP1 usage probably being proportional to the obesity rate, what is the basis for assuming there is disproportionately fewer people in Germany using these medications? Most people don't announce it.